Status:

WITHDRAWN

A Phase III Study of Efficacy of Lactobacillus CD2 Lozenges in Preventing High-Dose Chemotherapy Induced Oral Mucositis in Patients Undergoing Myeloablative Hematopoietic Stem Cell Transplantation

Lead Sponsor:

All India Institute of Medical Sciences

Conditions:

Oral Mucositis in Patients Undergoing HSCT

Eligibility:

All Genders

10-70 years

Phase:

PHASE3

Brief Summary

The study will be conducted at departments of Medical Oncology and Hematology, All India Institute of Medical Sciences (AIIMS). Patients with various malignancies who are taken up for high dose chemo...

Detailed Description

Study Design Placebo controlled double blind randomized, multi center clinical trial. Study Population and Number of Subjects Total of 108 patients undergoing myeloablative allogeneic or autologous h...

Eligibility Criteria

Inclusion

  • Age between 10 and 70 years.
  • Karnofsky Performance Score ≥ 70%.
  • Confirmed histological diagnosis of cancer/leukaemia for which haematopoietic stem cell transplantation is as approved modality of therapy.
  • Patients eligible to receive high-dose chemotherapy as part of conditioning regime.
  • Concomitant co morbid condition if present, controlled by medicines.
  • Serum creatinine upto 1.8mg/dl.
  • Total bilirubin 2mg/dl.
  • Liver enzymes within three times of normal limit.
  • Expected survival \> 6 months.

Exclusion

  • Pregnant women and lactating mothers.
  • Patients with history of AIDS
  • Patients who have taken any other investigational product in last 4 weeks.
  • Patients having untreated symptomatic dental infection.
  • Patients with WHO Grade 3 or 4 oral Mucositis.
  • Other serious concurrent illness.
  • Inconclusive histological diagnosis.
  • Patients on anticancer antibiotics.
  • Patients with signs and symptoms of systemic infections.
  • Patient's/guardian's refusal to sign informed consent.

Key Trial Info

Start Date :

November 1 2015

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2016

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT01797952

Start Date

November 1 2015

End Date

December 1 2016

Last Update

November 9 2016

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Institute Rotary Cancer Hospital,All India Institute of Medical Sciences

New Delhi, National Capital Territory of Delhi, India, 110029

A Phase III Study of Efficacy of Lactobacillus CD2 Lozenges in Preventing High-Dose Chemotherapy Induced Oral Mucositis in Patients Undergoing Myeloablative Hematopoietic Stem Cell Transplantation | DecenTrialz